An ancient signaling pathway and 20 years of research offer hope for rare cancer

byPeter MacCallum Cancer CentreCredit:EMBO Reports(2024). DOI: 10.1038/s44319-024-00217-3Researchers at Peter Mac are using their knowledge of an ancient signaling pathway to find ne

Updated on: September 07,2024

An ancient signaling pathway and 20 years of research offer hope for rare cancer

byPeter MacCallum Cancer CentreCredit:EMBO Reports(2024). DOI: 10.1038/s44319-024-00217-3Researchers at Peter Mac are using their knowledge of an ancient signaling pathway to find ne

Updated on:September 07,2024

US requires new info on breast density with all mammograms

by Matthew PerroneA radiologist uses a magnifying glass to check mammograms for breast cancer in Los Angeles, May 6, 2010. U.S. women getting mammograms will soon receive information about their breas

Updated on: January 02,2024

US requires new info on breast density with all mammograms

by Matthew PerroneA radiologist uses a magnifying glass to check mammograms for breast cancer in Los Angeles, May 6, 2010. U.S. women getting mammograms will soon receive information about their breas

Updated on:January 02,2024

Immunotherapy research offers new hope for children with primary liver carcinomas

by Jessica Cerretani,Children's Hospital BostonSwimmers plots for each individual patient course. Credit:eBioMedicine(2024). DOI: 10.1016/j.ebiom.2024.105147Pediatric hepatocellu

Updated on: September 07,2024

Immunotherapy research offers new hope for children with primary liver carcinomas

by Jessica Cerretani,Children's Hospital BostonSwimmers plots for each individual patient course. Credit:eBioMedicine(2024). DOI: 10.1016/j.ebiom.2024.105147Pediatric hepatocellu

Updated on:September 07,2024

Researchers uncover how breast cancer cells become resistant to therapy

by Molly Chiu,Baylor College of MedicineCredit: Unsplash/CC0 Public DomainAbout one-fourth of recurrent estrogen receptor-positive (ER+) breast cancers lose ER expression, which renders them res

Updated on: February 24,2024

Researchers uncover how breast cancer cells become resistant to therapy

by Molly Chiu,Baylor College of MedicineCredit: Unsplash/CC0 Public DomainAbout one-fourth of recurrent estrogen receptor-positive (ER+) breast cancers lose ER expression, which renders them res

Updated on:February 24,2024

Too often, women aren't told of sexual side effects of cancer treatments

by Cara MurezWhen a man has cancer in an area that affects sexual function, his doctor is likely to discuss it with him.But the same is not true for a woman who has cancer in a sex organ, according to

Updated on: January 02,2024

Too often, women aren't told of sexual side effects of cancer treatments

by Cara MurezWhen a man has cancer in an area that affects sexual function, his doctor is likely to discuss it with him.But the same is not true for a woman who has cancer in a sex organ, according to

Updated on:January 02,2024

Healthy gut bacteria can help fight cancer in other parts of the body, researchers find

by UT Southwestern Medical CenterImmune checkpoint therapy (ICT) helps gut microbiota travel from the gut to the lymph nodes where they activate immune cells (dendritic cells and T cells). Ultima

Updated on: February 01,2024

Healthy gut bacteria can help fight cancer in other parts of the body, researchers find

by UT Southwestern Medical CenterImmune checkpoint therapy (ICT) helps gut microbiota travel from the gut to the lymph nodes where they activate immune cells (dendritic cells and T cells). Ultima

Updated on:February 01,2024

Experimental monoclonal antibodies can coax aggressive prostate and breast cancers into submission, finds research

by Delthia Ricks , Medical XpressTherapeutic inhibition of VEGF binding to NRP2 activates anti-tumor immunity in a syngeneic model of prostate cancer that is resistant to aPD-L1 therapy. (A) Shown is

Updated on: January 23,2024

Experimental monoclonal antibodies can coax aggressive prostate and breast cancers into submission, finds research

by Delthia Ricks , Medical XpressTherapeutic inhibition of VEGF binding to NRP2 activates anti-tumor immunity in a syngeneic model of prostate cancer that is resistant to aPD-L1 therapy. (A) Shown is

Updated on:January 23,2024

New imaging technology for diagnosing and treating bowel cancer patients

byUniversity of GlasgowRepresentative transverse PET images from each mouse model and tracer. Credit:Clinical Cancer Research(2024). DOI: 10.1158/1078-0432.CCR-23-1063Biopsies are cu

Updated on: March 30,2024

New imaging technology for diagnosing and treating bowel cancer patients

byUniversity of GlasgowRepresentative transverse PET images from each mouse model and tracer. Credit:Clinical Cancer Research(2024). DOI: 10.1158/1078-0432.CCR-23-1063Biopsies are cu

Updated on:March 30,2024

Study identifies new gene that drives colon cancer

by The Mount Sinai HospitalRecurrently dysregulated super-enhancers in CRC patients.aStudy overview. Figure adapted from SMART Servier Medical Art, reproduced with permission, license

Updated on: February 18,2024

Study identifies new gene that drives colon cancer

by The Mount Sinai HospitalRecurrently dysregulated super-enhancers in CRC patients.aStudy overview. Figure adapted from SMART Servier Medical Art, reproduced with permission, license

Updated on:February 18,2024

Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainNovel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnose

Updated on: February 01,2024

Over half of English patients with NSCLC in areas with low socio-economic levels do not receive anti-cancer therapies

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainNovel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnose

Updated on:February 01,2024

A study refines a molecular marker that accurately predicts the recurrence of aggressive meningiomas

by Texas Children's HospitalCredit: Pixabay/CC0 Public DomainDrs. Akash Patel and Tiemo Klisch, investigators at the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Childr

Updated on: February 19,2024

A study refines a molecular marker that accurately predicts the recurrence of aggressive meningiomas

by Texas Children's HospitalCredit: Pixabay/CC0 Public DomainDrs. Akash Patel and Tiemo Klisch, investigators at the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Childr

Updated on:February 19,2024

Adcetris FDA approval expanded to include later-stage Hodgkin's

(HealthDay)—U.S. Food and Drug Administration approval of Adcetris (brentuximab vedotin) has been expanded to include adults with untreated stage III or IV classical Hodgkin's lymphoma, the agency

Updated on: March 30,2024

Adcetris FDA approval expanded to include later-stage Hodgkin's

(HealthDay)—U.S. Food and Drug Administration approval of Adcetris (brentuximab vedotin) has been expanded to include adults with untreated stage III or IV classical Hodgkin's lymphoma, the agency

Updated on:March 30,2024